

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

NCT07290803

Status	RECRUITING
Sponsor	Sanofi
Enrollment	1,000 participants

Key Eligibility Criteria

Inclusion (4)

- Patients aged more than or equal to (e) 12 years at the time of consent.
- Confirmed diagnosis of AD, of any severity, according to the Investigator's assessment as aligned with International Classification of Diseases 10th revision (ICD-10) code of L20.
- Prescribed and scheduled to initiate any systemic treatment for AD (including but not limited to biologics, oral Janus kinase (JAK) inhibitors, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil)
- Signed informed consent for registry participation by the patient or parent/legal representative and assent by the patient appropriate to the patient's age, including willingness to participate in long-term follow-up.

Exclusion (3)

- Concurrent participation in an interventional clinical trial that administers an investigational drug that modifies patient care.
- Insufficient understanding of the study by the patient and/or parent/guardian.
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (37 total)

Cahaba Dermatology & Skin Health Center- Site Number : 8400006, Birmingham, Alabama, United States

River Region Dermatology and Laser- Site Number : 8400041, Montgomery, Alabama, United States

San Tan Allergy & Asthma- Site Number : 8400031, Gilbert, Arizona, United States

... and 34 more locations